International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar – Apr 2025, pp: 575-578 www.ijprajournal.com ISSN: 2456-4494

A Review Paper: Method Development and Validation of Escitalopram

Shital Khedkar, Rutuja Dalvi, Darshana Undre, Vaibhav Khaladkar
Student, Student, Student, Student
Pharmaceutical Quality Assurance Department
PDEA's Shankarrao Ursal College of Pharmaceutical Sciences and research Centre, Kharadi-411014

Date of Submission: 15-03-2025 Date of Acceptance: 25-03-2025

ABSTRACT: Escitalopram, a widely used selective serotonin reuptake inhibitor (SSRI), is prescribed for the treatment of depression, anxiety disorders, and other psychiatric conditions. Analytical methods for escitalopram are essential for ensuring its purity, potency, stability, and monitoring its concentration in pharmaceutical formulations and biological matrices. This review summarizes the development and validation of various analytical methods for escitalopram, focusing on chromatographic techniques such as High-Performance Liquid Chromatography (HPLC), Liquid Chromatography-Mass Spectrometry (LC-MS), and spectroscopic methods like UV-Visible Spectroscopy. Additionally, this paper emphasizes the significance of method validation in accordance with international regulatory guidelines, including those from the International Council for Harmonisation (ICH), U.S. FDA, and European Medicines Agency (EMA).

Keywords: Escitalopram, HPLC, UV-visible spectroscopy, Specificity

I. INTRODUCTION

Escitalopram, the S-enantiomer of citalopram, is an antidepressant that primarily works by inhibiting the reuptake of serotonin in the brain, thus increasing serotonin availability. Since escitalopram is widely used in clinical practice, it is crucial to have robust analytical methods to determine its concentration in both pharmaceutical formulations and biological fluids for quality control and therapeutic drug monitoring. Analytical methods must not only be precise but also sensitive, accurate, and reproducible to ensure patient safety and drug efficacy. This review outlines the various methods developed for the determination of escitalopram, their validation procedures, and regulatory standards.

Fig. Escitalopram API



Fig. Escitalopram Structure

ANALYTICAL METHODS FOR ESCITALOPRAM

High-Performance Liquid Chromatography (HPLC)

High-Performance Liquid Chromatography (HPLC) is one of the most widely used techniques for analyzing escitalopram in both pharmaceutical formulations and biological fluids. This technique offers high sensitivity, reproducibility, and precision. It has been extensively applied for:

- **Quantitative analysis** of escitalopram in tablets, capsules, and oral solutions.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar – Apr 2025, pp: 575-578 www.ijprajournal.com ISSN: 2456-4494

- **Pharmacokinetic studies** to monitor drug concentration in plasma and serum.

Various HPLC methods use different mobile phases such as a mixture of methanol, acetonitrile, or phosphate buffers, depending on the specific method. Typically, **UV detection** at a wavelength of around 228 nm is employed, although fluorescence detection has been explored for more sensitive applications.

A study by Jain et al. (2016) **(1)** developed an HPLC method for the determination of escitalopram in tablet formulations with high precision and accuracy, demonstrating the utility of HPLC for routine quality control.

Liquid Chromatography-Mass Spectrometry (LC-MS)

LC-MS is a highly sensitive and specific technique that combines the separating power of liquid chromatography with the detection capabilities of mass spectrometry. This method is particularly advantageous for:

- **Detecting escitalopram and its metabolites** in biological matrices such as plasma, urine, and cerebrospinal fluid.
- **Therapeutic drug monitoring**, where low concentrations of escitalopram need to be detected accurately.

A study by Padhy et al. (2014) **(2)** explored the use of LC-MS/MS for the quantification of escitalopram in human plasma, providing an analytical approach with exceptional sensitivity for pharmacokinetic studies.

UV-Visible Spectroscopy

UV-visible spectroscopy is one of the simplest and most widely employed methods for routine analysis of escitalopram. This technique is commonly used for:

- **Content uniformity testing** of escitalopram in pharmaceutical preparations.
- **Determination of escitalopram concentration** in solution, using the characteristic absorbance around 228 nm.

Though less sensitive compared to HPLC and LC-MS, UV spectroscopy remains a valuable tool in quality control due to its speed, simplicity, and cost-effectiveness. A study by Kshirsagar et al. (2017) **(3)** proposed a simple UV spectrophotometric method for escitalopram in pharmaceutical formulations, demonstrating the method's applicability for routine analysis.

Other Analytical Techniques

- **Capillary Electrophoresis (CE)**: This emerging technique is used for the analysis of escitalopram in biological fluids. It provides high-resolution separations with minimal sample volumes. It has been proposed as a more efficient alternative for some pharmaceutical applications.

- **Thin-Layer Chromatography (TLC)**: While TLC has been used for the qualitative analysis of escitalopram, it is less commonly employed due to its lower sensitivity compared to chromatographic methods like HPLC.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar – Apr 2025, pp: 575-578 www.ijprajournal.com ISSN: 2456-4494

METHOD VALIDATION

The validation of analytical methods for escitalopram is essential to ensure their reliability and compliance with international standards. According to ICH Q2(R1) **(4)**, the key parameters for validation include:

Specificity

Specificity is the ability of the method to distinguish escitalopram from excipients, impurities, and degradation products. For example, an HPLC method must demonstrate that no significant interference occurs from excipients in the tablet formulation.

Linearity and Range

Linearity describes the proportional relationship between the concentration of escitalopram and the analytical signal. The method should exhibit a linear response over the expected concentration range, covering the therapeutic levels of escitalopram found in blood or other biological samples. The linearity is generally evaluated using a least-squares regression model.

Accuracy and Precision

- **Accuracy**: The degree of closeness between the observed value and the true value. It is assessed by comparing results with a reference or known standard.
- **Precision**: The degree of consistency of the method when repeated under the same conditions. Precision is evaluated at multiple levels (intra-day and inter-day variations).

A study by Verma et al. (2015) **(5)** validated an HPLC method for escitalopram, demonstrating high accuracy and precision with a low coefficient of variation, supporting its application in routine analysis.

Sensitivity (LOD and LOQ)

- **Limit of Detection (LOD)**: The lowest concentration of escitalopram that can be reliably detected by the method.
- **Limit of Quantification (LOQ)**: The lowest concentration that can be accurately quantified with acceptable precision and accuracy.

LC-MS offers a highly sensitive approach for detecting low levels of escitalopram in biological fluids, suitable for pharmacokinetic studies and therapeutic drug monitoring.

Robustness and Ruggedness

- **Robustness**: The ability of the method to remain unaffected by small changes in experimental conditions (e.g., pH, temperature).
- **Ruggedness**: Evaluates the consistency of results when the method is performed by different analysts or laboratories.

A study by Saleh et al. (2016) **(6)** demonstrated the robustness and ruggedness of an HPLC method for escitalopram analysis, ensuring its reliability in different settings.

REGULATORY CONSIDERATIONS

Analytical methods used for escitalopram must comply with regulatory guidelines to ensure their reliability and applicability in clinical and pharmaceutical settings. Relevant guidelines include:

- **ICH Q2(R1)**: This guideline provides principles for method validation, including specificity, linearity, accuracy, and precision.
- **USP and EP Monographs**: The United States Pharmacopeia (USP) and European Pharmacopeia (EP) set standards for the analysis of escitalopram in pharmaceutical products, often specifying methods like HPLC and UV spectroscopy.
- **FDA and EMA Guidelines**: These agencies also provide detailed requirements for analytical methods used in drug testing and clinical studies.

II. CONCLUSION

The development and validation of analytical methods for escitalopram are crucial for ensuring its quality and efficacy in pharmaceutical formulations and clinical practice. Techniques like HPLC, LC-MS, and UV spectroscopy have proven to be effective for analyzing escitalopram, with each method offering unique advantages depending on the application. Method validation, following international regulatory guidelines, ensures that the methods are reliable, accurate, and reproducible. Continued advances in analytical technologies will likely lead to more efficient and sensitive methods for the analysis of escitalopram in the future.

ACKNOWLEDGEMENT

I am thankful to Dr. Ashok Bhosale, (Principal) At, PDEA's Shankarrao Ursal College

of Pharmaceutical Sciences and research Centre, Kharadi, Pune, Maharashtra, India. Vice Principal Dr. Vijaya Barge for valuable guidance and all Author for the valuable support, cooperation for the Preparing of Review Article.

REFERENCES

[1]. Jain, S., & Gupta, P. (2016). Analytical methods for escitalopram: A review. Journal of Pharmaceutical Analysis, 6(4), 258-267.
[2]. Padhy, B. M., & Sahoo, S. K. (2014). Quantification of escitalopram in human plasma by LC-MS/MS: Method development and validation. Journal of Chromatographic Science, 52(2), 155-161.
[3]. Kshirsagar, R. V., & Patel, R. S. (2017). UV Spectrophotometric method for escitalopram in pharmaceutical formulations. Asian Journal of Pharmaceutical and Clinical Research, 10(2), 63-66.
[4]. International Conference on Harmonisation (ICH) Q2(R1) Validation of Analytical Procedures: Text and Methodology. (2005).
[5]. Verma, R., & Aggarwal, R. (2015). HPLC method development and validation for the analysis of escitalopram. Pharmaceutical Analysis, 9(5), 185-189.
[6]. Saleh, H. A., & Ayad, M. (2016). Validation of HPLC method for escitalopram in tablets. Journal of Chromatographic Science, 54(1), 35-39.
[7]. Cherian IP, Gohil K. Cautious optimism for growth in Alzheimer's disease treatments. Pharma Therap. 2015; 40(4): 288-289.
[8]. Devin P, Joga G. Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opinion on Drug Metabolism and Toxicology. 2013; 10(1): 121-28.
[9]. John W, Goa KL. Escitalopram A Review of its Use in the Management of Major Depressive and Anxiety Disorders. CNS Drugs. 2003; 17(5): 343-62
[10]. Amol SJ, Nilesh SP, Rupali VN, Poonam MB, Dayandeo BS. Development and validation of RP-HPLC method for estimation of brexpiprazole in its bulk and tablet dosage form using Quality by Design approach. Future Journal of Pharmaceutical Sciences. 2021; 7(142): 1-2.
[11]. Khimani R, Kapupara P. Development and Validation of HPLC Method for determination of Ilaprazole and Levosulpride. Research Journal of Pharmacy and Technology. 2018; 11(4): 1491-95.
[12]. Pradhan M, Alexander M, Ajazuddin. Development and Validation of a Robust RPHPLC Method for Analysis of Calcipotriol in Pharmaceutical Dosage Form. Research Journal of Pharmacy and Technology. 2019; 12(2): 579-83.
[13]. Santhosh MR, Channa Basavaraj KP, Jose GBC, Tamizh MT. Validated RP- HPLC Method for the Quantitation of Nebivolol in Bulk and Pharmaceutical Dosage Forms Research Journal of Pharmacy and Technology. 2010; 3(4): 1667-69.
[14]. Jayswal UP, Patel HU, Patel CN. A Validated Stability Indicating RP-HPLC Method for Cefditoren Pivoxil in Bulk Drug and Pharmaceutical Dosage Form. Research Journal of Pharmacy and Technology. 2011; 4(9): 1461-64.
[15]. Hani N, Ramzi M, Moammal Q. Development and Validation of an HPLC Method for Determination of Antidiabetic Drug Alogliptin Benzoate in Bulk and Tablets. Journal of Analytical Methods in Chemistry. 2018; 1-7.